Q2 Earnings Estimate for Cryoport Issued By Leerink Partnrs

Cryoport, Inc. (NASDAQ:CYRX) – Equities research analysts at Leerink Partnrs boosted their Q2 2025 earnings estimates for Cryoport in a research note issued to investors on Wednesday, May 7th. Leerink Partnrs analyst P. Souda now expects that the company will post earnings of ($0.21) per share for the quarter, up from their prior forecast of ($0.22). The consensus estimate for Cryoport’s current full-year earnings is ($0.99) per share. Leerink Partnrs also issued estimates for Cryoport’s Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.76) EPS and FY2026 earnings at ($0.77) EPS.

Cryoport (NASDAQ:CYRX) last issued its earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The company had revenue of $41.04 million for the quarter, compared to analyst estimates of $56.19 million.

Several other analysts also recently issued reports on the stock. UBS Group upped their price target on shares of Cryoport from $10.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday, April 1st. Roth Mkm reaffirmed a “buy” rating and issued a $15.00 price target on shares of Cryoport in a report on Tuesday, April 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price target on shares of Cryoport in a report on Thursday, May 8th. Morgan Stanley reduced their price target on shares of Cryoport from $8.00 to $7.00 and set an “equal weight” rating on the stock in a report on Monday, May 5th. Finally, Guggenheim reissued a “buy” rating and set a $10.00 price objective on shares of Cryoport in a research note on Wednesday, April 16th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Cryoport Trading Down 2.4%

Shares of CYRX opened at $6.98 on Monday. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. The firm’s 50-day moving average is $5.90 and its two-hundred day moving average is $6.87. Cryoport has a twelve month low of $4.58 and a twelve month high of $14.21. The firm has a market capitalization of $349.96 million, a P/E ratio of -2.07 and a beta of 1.92.

Insider Activity at Cryoport

In other Cryoport news, CEO Jerrell Shelton sold 4,620 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $29,059.80. Following the transaction, the chief executive officer now owns 765,399 shares of the company’s stock, valued at $4,814,359.71. This trade represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 19,830 shares of company stock valued at $118,353. Company insiders own 10.00% of the company’s stock.

Hedge Funds Weigh In On Cryoport

Large investors have recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. raised its stake in Cryoport by 148.7% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock worth $28,000 after purchasing an additional 2,120 shares during the period. Lazard Asset Management LLC purchased a new position in Cryoport during the fourth quarter worth approximately $51,000. Avanza Fonder AB purchased a new position in Cryoport during the fourth quarter worth approximately $64,000. SBI Securities Co. Ltd. raised its stake in Cryoport by 548,750.0% during the first quarter. SBI Securities Co. Ltd. now owns 10,977 shares of the company’s stock worth $67,000 after purchasing an additional 10,975 shares during the period. Finally, Quarry LP purchased a new position in Cryoport during the fourth quarter worth approximately $69,000. Hedge funds and other institutional investors own 92.90% of the company’s stock.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.